{"id":39301,"key":"Global_Health_Medical_Device_Compendium/Guava_Auto_CD4-CD4%_System","title":"Global Health Medical Device Compendium/Guava Auto CD4-CD4% System","latest":{"id":1267648,"timestamp":"2026-09-10T14:03:01Z"},"content_model":"wikitext","license":{"url":"https://www.appropedia.org/Appropedia:Copyrights","title":"CC-BY-SA-4.0"},"source":"[[File:Guava automated.jpg|thumb]]\n\n{{GHMDC device data\n| health-topic = HIV/AIDS\n| classification = Diagnosis\n| scope = Commercialized\n| replicated = No\n| manufacturer-location = Massachusetts, United States\n}}\n\nCD4 T cell counts are necessary for the monitoring and diagnosis of HIV/AIDS. These tests are often difficult and expensive. A low-cost, easy to use option is needed for use in resource-limited settings.\n\n== Detailed description of the solution ==\n\nThe Guava Auto CD4/CD4% System is a unique bench-top instrument equiped with acquisition software that health providers can use to easily monitor patients' T-lymphocytes. The Guava Auto CD4/CD4% System provides reliable results with minimum technical expertise to operate. The system provides absolute CD4 counts, CD4% of total lymphocytes, and total lymphocyte count.\n\n== Designed by ==\n\n* Designed by: Guava Technologies, Inc., but Millipore acquired Guava in 2009.\n* Manufacturing: Headquarters located in Billerica, Massachusetts, USA.\n\n== When and where it was tested/implemented ==\n\nTesting of the device has been done in the United States. Performance has been evaluated in multiple laboratories against several well-accepted methods for determining absolute CD4 counts and CD4% values. Studies were performed on both adult and pediatric HIV samples as well as normal samples. Auto CD4/CD4% Assay test results were compared to results from other well established methods for CD4 analysis, showing consistently comparable results.\n\n== References ==\n\n=== Peer-reviewed publication ===\n\nThe 2009 WHO \"Review of CD4 Technologies\" stated that there have been no peer-reviewed independent performance evaluation data for the Guava Auto CD4. PDF cited [http://www.who.int/hiv/topics/treatment/review-of-cd4-technologies.pdf here].\n\n=== Other internally generated reports ===\n\n* [https://www.merckmillipore.com/GT/es/20160218_190610 Information at the Merck webpage]\n\n=== Externally generated reports ===\n\nMergia, A., Elad, K., Sharp, M., Fishwild, D., O'Connell, B., Bredt, B., & Tyagarajan, K. (February, 2005). Performance of Aged, TransFix-Treated Blood in the Guava EasyCD4 and EasyCD8 Assays. Guava Technologies. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts USA.\n\n{{Page data\n| sdg = SDG03 Good health and well-being\n| organizations = Merck Millipore\n| license = CC-BY-SA-3.0\n| language = en\n}}"}